These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11600607)

  • 1. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels.
    Rustin GJ; Marples M; Nelstrop AE; Mahmoudi M; Meyer T
    J Clin Oncol; 2001 Oct; 19(20):4054-7. PubMed ID: 11600607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
    Rustin GJ; Timmers P; Nelstrop A; Shreeves G; Bentzen SM; Baron B; Piccart MJ; Bertelsen K; Stuart G; Cassidy J; Eisenhauer E
    J Clin Oncol; 2006 Jan; 24(1):45-51. PubMed ID: 16382112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of CA-125 to assess response to new agents in ovarian cancer trials.
    Rustin GJ
    J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
    Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
    J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.
    Rustin GJ; Nelstrop AE; Tuxen MK; Lambert HE
    Ann Oncol; 1996 Apr; 7(4):361-4. PubMed ID: 8805927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
    But I; Gorisek B
    Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
    Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
    Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
    Rustin GJ; Nelstrop AE; McClean P; Brady MF; McGuire WP; Hoskins WJ; Mitchell H; Lambert HE
    J Clin Oncol; 1996 May; 14(5):1545-51. PubMed ID: 8622070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure.
    Folk JJ; Botsford M; Musa AG
    Gynecol Oncol; 1995 May; 57(2):178-82. PubMed ID: 7729730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.
    Bridgewater JA; Nelstrop AE; Rustin GJ; Gore ME; McGuire WP; Hoskins WJ
    J Clin Oncol; 1999 Feb; 17(2):501-8. PubMed ID: 10080591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
    Crawford SM; Peace J
    Ann Oncol; 2005 Jan; 16(1):47-50. PubMed ID: 15598937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
    Han LY; Karavasilis V; Hagen Tv; Nicum S; Thomas K; Harrison M; Papadopoulos P; Blake P; Barton DP; Gore M; Kaye SB
    Eur J Cancer; 2010 May; 46(8):1359-64. PubMed ID: 20303743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
    Kang S; Seo SS; Park SY
    J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
    Lan CY; Huang H; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
    Meisel M; Straube W; Weise J; Burkhardt B
    Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    Markman M; Liu PY; Rothenberg ML; Monk BJ; Brady M; Alberts DS
    J Clin Oncol; 2006 Mar; 24(9):1454-8. PubMed ID: 16549840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.